A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

To evaluate the safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children with HIV. DESIGN: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilck, Marissa, Barnabas, Shaun, Chokephaibulkit, Kulkanya, Violari, Avy, Kosalaraksa, Pope, Yesypenko, Svitlana, Chukhalova, Iryna, Dagan, Ron, Richmond, Peter, Mikviman, Elena, Morgan, Leslie, Feemster, Kristen, Lupinacci, Robert, Chiarappa, Joseph, Madhi, Shabir A., Bickham, Kara, Musey, Luwy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241418/
https://www.ncbi.nlm.nih.gov/pubmed/36939067
http://dx.doi.org/10.1097/QAD.0000000000003551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241418/
https://www.ncbi.nlm.nih.gov/pubmed/36939067
http://dx.doi.org/10.1097/QAD.0000000000003551

Ejemplares similares